Jeffrey Totten, Vice President, Dean & Company
Chairperson’s Opening Remarks Tuesday, October 6th
Anne Dollard, Deputy General Counsel, Chief Patent Counsel, Takeda San Francisco
KEYNOTE PANEL: Adopting Best Practices To Expedite Due Diligence Processes
Alison Shurell, Vice President of Life Sciences Marketing, IntraLinks
KEYNOTE PANEL: Adopting Best Practices To Expedite Due Diligence Processes
Ira Weiss, Board of Directors, Corporate Secretary, BioDtech, Inc.
Effectively Utilizing The Term Sheet To Strengthen Partnership Agreements
Peter Joiner, Chief Executive Officer, Madeira Therapeutics
PANEL: Survival Strategies In A Down Economy: How Small Biotechs Are Remaining Strong
Yan Lavrovsky, Chief Executive Officer, Avineuro
PANEL: Survival Strategies In A Down Economy: How Small Biotechs Are Remaining Strong
Dennis Kim, MD, Senior Vice President, Medical Affairs and Communication, Orexigen
PANEL: Survival Strategies In A Down Economy: How Small Biotechs Are Remaining Strong
Mark Benedyk, Head, The Pfizer Incubator LLC
PANEL: Survival Strategies In A Down Economy: How Small Biotechs Are Remaining Strong
Len Smith, Senior Intellectual Property Counsel, Novo Nordisk
The Winning Combination – Effective Collaboration Between IP & BD Professionals
Paul Cayer, Chief Business Officer, Otonomy, Inc.
Therapeutic Area Snapshots
Jacob Licht, Director, Corporate Development, Emergent BioSolutions
Leveraging Your Assets To Expand Your Pipeline
Martin Reeves, VP Business Development, Cephalon
Rome Couldn't Be Built In A Day And Nor Can A New Therapeutic Business--The Latter Takes About 6 Weeks
Peter Joiner, Chief Executive Officer & President, Madeira Therapeutics
The Need For FDA Approved Pediatric Medications